Nanocomposite for Targeted Degradation of Pathogenic Proteins
Summary
USPTO published patent application US20260091129A1 by inventors Zhang et al. disclosing a nanocomposite system for targeted degradation of pathogenic proteins using a maleimide-PEG-PLA nanocarrier with cationic lipids and protein-targeting binding peptides. The invention enables degradation of protein aggregates through autophagy pathways, addressing limitations of PROTAC and LYTAC technologies, with applications in anti-tumor treatments and Huntington's disease.
What changed
This patent application discloses a nanocomposite comprising a maleimide-polyethylene glycol-polylactic acid nanocarrier assembled with cationic lipids, grafted with protein-targeting binding peptides for selective autophagy-mediated degradation of pathogenic proteins. The inventors claim advantages over existing PROTAC technology (unable to degrade large protein aggregates) and LYTAC technology (unable to degrade cytoplasmic proteins), with specific applications in anti-tumor nanodrugs and Huntington's disease treatment.
Patent applicants and companies developing targeted protein degradation therapeutics should review the claims for freedom-to-operate implications. While no immediate compliance action is required, R&D teams should monitor this patent landscape for potential licensing opportunities or competitive positioning in the targeted protein degradation space.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
NANOCOMPOSITE FOR TARGETED DEGRADATION OF PATHOGENIC PROTEIN, PREPARATION METHOD THEREFOR, AND USE THEREOF
Application US20260091129A1 Kind: A1 Apr 02, 2026
Inventors
Yunjiao Zhang, Xiaowan Huang, Ziyang Cao, Xianzhu Yang, Longping Wen
Abstract
Provided are a nanocomposite for targeted degradation of a pathogenic protein, a preparation method therefor, and use thereof, which pertain to the technical field of nanobiological drugs. The nanocomposite for targeted degradation of the pathogenic protein is provided, which comprises a nanocarrier and a protein-targeting binding peptide grafted on the nanocarrier. The nanocarrier is a nanoassembly of maleimide-polyethylene glycol-polylactic acid and cationic lipids; on the other hand, the use of the nanocomposite in the preparation of drugs including an anti-tumor nanodrug and a Huntington's disease inhibiting drug is provided. The nanocomposite can simulate a key receptor protein in a selective autophagy pathway, so that the pathogenic protein to be degraded can be brought into an autophagosome to be degraded by means of an autophagy pathway, thereby effectively solving the problem that PROTACs cannot degrade large-molecular-weight protein aggregates and LYTACs cannot degrade cytoplasmic proteins.
CPC Classifications
A61K 47/6937 A61K 9/5123 A61K 9/5153 A61K 9/5192 A61K 33/243 A61K 45/06 A61K 47/543 A61K 47/62 A61P 25/28 A61P 35/00 C07K 14/705
Filing Date
2023-08-17
Application No.
19111784
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Peptides (C07K) publishes new changes.